ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: Carbone To Leave NCI for Wisconsin ACS’ Holleb Says Tobacco Industry Tries to Hide Ad Warning

October 3, 1975

USC Scientists Says It’s Time Nobelists Recognize Value of Cancer Program

February 10, 1978

FIT More Effective Than gFOBT In All Colonoscopy Capacities

November 25, 2011

National Cancer Survey Data Available Soon: NCI Will Invite Investigators to Prepare Analysis

August 23, 1974

RFPs Available

May 5, 2000

DCT Board Oks Limited Support For Development Of Neutron Therapy

March 31, 1978